PDCD1 and head and neck squamous cell carcinoma: Similarly, a phase 2 trial (NCT03468218) of pembrolizumab plus cabozantinib, a VEGFR, MET, AXL, and FLT3 tyrosine kinase inhibitor, reported a 52% ORR and median PFS of 12.8 months, driven by dual targeting of VEGF and PD-1 pathways, with a 2-year PFS of 32.6% and manageable toxicity, suggesting a promising alternative for R/M HNSCC [118].